Chapter

Biological targets and new drug development for prostate cancer

Shahneen Sandhu and Johann DeBono

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0010

Series: Oxford Oncology Library

Biological targets and new drug development for prostate cancer

Show Summary Details

Preview

• Androgen receptor (AR) signalling is usually necessary for the development and progression of prostate cancer • Androgen depletion is the mainstay of treatment for advanced prostate cancer but responses can be short-lived • AR-signalling frequently remains intact as prostate cancer evolves from androgen sensitive to castration resistant disease (CRPC) • A number of mechanisms may facilitate AR reactivation, including AR overexpression, AR mutation leading to promiscuous ligand binding or constitutive activation, adrenal and intratumoral androgen synthesis, and activated signal transduction pathways • The AR signalling pathway remains a rational therapeutic target in CRPC.

Chapter.  3400 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.